No abstract

NEURO-ONCOLOGY • NOVEMBER 2017with prior chemotherapy. 1 patient was not evaluable at 3 months. With a median follow-up of 14.3 months (2-24 months), PFS6 was 58.2% (95% CI33.5-76.5%) and PFS12 was 38% (95% CI16-60%). Overall survival at 12 months was 68% (95% CI42.1%-84.2%). By central review, volumetric analysis at 3 months demonstrated a decrease in tumor volume superior to 10% in 8 tumors (4 patients). Pretherapeutic growth rate was decreased of more than 50% in 29/35 tumors (18/20 patients) during the first 3 months. Inclusion-to-3 months tumor growth rate (mean at 1.9%/month) was significantly lower than preinclusion-to-inclusion growth rate (mean at 18.5%/ month) (p=0.0003). Toxicity included stomatitis (10, 50%) and 7 grade III AE (stomatitis, 3; pneumopathy, 1). SST2 receptor expression was not correlated with PFS and growth rate. P70 IHC and genomic studies are ongoing. CONCLUSION: Everolimus and octreotide combination appears active in refractory aggressive and progressive meningiomas with moderate toxicity, and should request further evaluation.